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Neutrophil-speciﬁc deletion of the CARD9
gene expression regulator suppresses
autoantibody-induced inﬂammation in vivo
Tama´s Ne´meth1,2, Krisztina Futosi1, Cassian Sitaru3, Ju¨rgen Ruland4 & Attila Mo´csai1,2
Neutrophils are terminally differentiated cells with limited transcriptional activity. The
biological function of their gene expression changes is poorly understood. CARD9 regulates
transcription during antifungal immunity but its role in sterile inﬂammation is unclear. Here
we show that neutrophil CARD9 mediates pro-inﬂammatory chemokine/cytokine but not
lipid mediator release during non-infectious inﬂammation. Genetic deﬁciency of CARD9
suppresses autoantibody-induced arthritis and dermatitis in mice. Neutrophil-speciﬁc
deletion of CARD9 is sufﬁcient to induce that phenotype. Card9 / neutrophils show
defective immune complex-induced gene expression changes and pro-inﬂammatory
chemokine/cytokine release but normal LTB4 production and other short-term responses. In
vivo deletion of CARD9 reduces tissue levels of pro-inﬂammatory chemokines and cytokines
but not LTB4. The CARD9-mediated signalling pathway involves Src-family kinases, Syk,
PLCg2, Bcl10/Malt1 and NFkB. Collectively, CARD9-mediated gene expression changes
within neutrophils play important roles during non-infectious inﬂammation in vivo and CARD9
acts as a divergence point between chemokine/cytokine and lipid mediator release.
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eutrophils are short-lived, terminally differentiated cells
that play critical roles in antimicrobial host defence and
also contribute to autoimmune and other non-infectious
inﬂammatory processes1–3. Unlike the long-lived macrophages
and dendritic cells, neutrophils have limited transcriptional
activity but instead show robust short-term effector functions
such as phagocytosis, respiratory burst, degranulation or NET
release. The dissociation of neutrophil function from gene
expression is best exempliﬁed by the fact that anuclear
neutrophils that have expelled their DNA through NETosis are
still capable of performing various in vivo antimicrobial
functions4. Based on their short lifespan, limited transcriptional
activity and robust short-term effector functions, neutrophils are
generally believed to be simple effector cells of the immune and
inﬂammatory reaction.
However, neutrophils have also been shown to be able to
upregulate pro-inﬂammatory gene expression and to release
various chemokines and cytokines5,6. Those non-conventional
functional responses may indicate a more general role of
neutrophils in the orchestration of the immune/inﬂammatory
response1,3,6. Unfortunately, it is still unclear whether
inﬂammation-related gene expression changes in neutrophils
(and the resulting chemokine/cytokine production) are just
evolutionary remnants from the macrophage-related origin of
these cells, or they play an important functional role during the
in vivo inﬂammation process. This uncertainty is primarily due to
the fact that none of the currently available in vivo models allow
suppression of gene expression changes in such a manner that it
is both selective for neutrophils and it also retains other
functional responses of neutrophils intact.
Caspase recruitment domain-containing protein 9 (CARD9) is
an intracellular adapter protein primarily expressed in myeloid-
lineage cells and couples C-type lectin receptors to NFkB-
mediated gene expression7. CARD9 plays a critical role in host
defence against fungal pathogens in both mice8–10 and
humans11,12, and it is also involved in immunity against
other microbial infections7,13. In addition to its antimicrobial
function, human genetic studies have also linked CARD9 to
highly prevalent human diseases of non-infectious origin
such as inﬂammatory bowel disease14–17, ankylosing
spondylitis18,19, rheumatoid arthritis20 or IgA nephropathy21.
However, it is still unclear whether CARD9 indeed participates
in non-infectious inﬂammation and if so, what are the cellular
and molecular pathways involved. In addition, though the
analysis of CARD9 function has so far focused on dendritic
cells and macrophages, CARD9 is also present in neutrophils12,22
and the ImmGen database23 indicates that neutrophils express
the highest level of CARD9 within the immune system.
Unfortunately, the role of CARD9 in neutrophils is still very
poorly understood.
Autoantibody-induced sterile inﬂammation is an important
component of autoimmune disease pathogenesis. Its experimental
models24–26 mimic important aspects of human rheumatoid
arthritis, bullous pemphigoid and epidermolysis bullosa acquisita.
Autoantibody-induced inﬂammation is mediated by sequential
activation of lipid (LTB4), cytokine and chemokine cascades27.
Neutrophils are critically involved in autoantibody-induced
sterile inﬂammation2,28 and we have previously shown that
autoantibody-induced inﬂammation is mediated by signalling
through Src-family kinases, Syk and PLCg2 (refs 29–32).
However, it is at present unclear how signalling downstream of
those receptor-proximal molecules triggers lipid, chemokine and
cytokine release.
The lack of knowledge on the contribution of neutrophil gene
expression to in vivo inﬂammation, on the role of CARD9 in
non-infectious inﬂammation and neutrophil function and on
how receptor-proximal signalling molecules are coupled to
inﬂammatory mediator release, prompted us to investigate the
role of CARD9 in autoantibody-mediated in vivo inﬂammation
models. Our results indicate that CARD9 mediates autoantibody-
induced inﬂammation by acting as a divergence point down-
stream of receptor-proximal signalling molecules triggering
chemokine and cytokine but not lipid mediator (LTB4) release.
Importantly, lineage-speciﬁc studies revealed that those functions
are primarily linked to CARD9 expression within neutrophils,
indicating a critical contribution of neutrophil gene expression
and chemokine/cytokine release to the overall in vivo
inﬂammatory reaction.
Results
The role of CARD9 in autoantibody-induced arthritis.
To test the role of CARD9 in non-infectious inﬂammation, we
tested the effect of CARD9 deﬁciency on autoantibody-induced
arthritis development in the K/BN serum-transfer model30.
We have used two independent CARD9-deﬁcient mouse
strains (Supplementary Fig. 1a) that were homozygous
either for the conventional Card9tm1Jrld knockout mutation
(referred to as Card9 / mice) or for the so-called knockout-
ﬁrst33 Card9tm1a(EUCOMM)Hmgu mutation (referred to as
Card9 / (EUCOMM) mice). CARD9 was absent from bone
marrow (Supplementary Fig. 1b) and spleen (Supplementary
Fig. 1c) cell lysates of both mutant strains. As indicated in Fig. 1a,
Card9 / mice showed substantially reduced signs of arthritis
development. Quantiﬁcation of the visible clinical signs (Fig. 1b;
P¼ 0.0028; two-way analysis of variance (ANOVA)), ankle
thickening (Fig. 1c; P¼ 0.0047; two-way ANOVA) and the
ability of the mice to hold on to the bottom of a wire grid
(Fig. 1d; P¼ 2 10–4; two-way ANOVA) all conﬁrmed highly
signiﬁcant protection from disease development. Similarly,
Card9 / (EUCOMM) mice were also strongly protected from
visible signs of arthritis (Fig. 1e; P¼ 6.6 10–4; two-way
ANOVA) and ankle thickening (Fig. 1f; P¼ 0.0038; two-way
ANOVA). Therefore, CARD9 plays a major role in the
development of autoantibody-induced arthritis.
We have also generated bone marrow chimeras by transplant-
ing CARD9-deﬁcient bone marrow cells to lethally irradiated
wild-type recipients. Similar to intact mice, Card9 / bone
marrow chimeras also showed partial protection from arthritis
development in the K/BN serum-transfer model
(Supplementary Figs 2a–d; P values between 9.1 10–11 and
1.6 10 4; two-way ANOVA), indicating a role for CARD9 in a
radiosensitive hematopoietic compartment.
The role of CARD9 in autoantibody-induced skin blistering.
We have also tested the effect of CARD9 deﬁciency on dermatitis
triggered by systemic administration of antibodies against
collagen VII (a mouse model of the human blistering skin disease
epidermolysis bullosa acquisita). Card9 / mice were sub-
stantially, though not completely protected from the visible skin
disease (Fig. 2a), which was also conﬁrmed by quantitative
analysis of the body surface area affected (Fig. 2b; P¼ 0.017;
two-way ANOVA) and the overall disease severity score (Fig. 2c;
P¼ 0.022; two-way ANOVA). This was not due to the reduced
circulating autoantibody concentration since serum levels
of collagen VII-speciﬁc IgG were similar in wild-type and
Card9 / mice (Fig. 2d; P¼ 0.95; two-way ANOVA).
Role of CARD9 in leukocyte recruitment and migration.
Flow cytometric analysis of myeloid cells in the synovial
inﬁltrate (Fig. 3a,b) revealed reduced accumulation of neutro-
phils (P¼ 0.0041; Student’s t-test) and macrophages (P¼ 0.026;
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Student’s t-test) at the site of inﬂammation in Card9 / mice
subjected to K/BN serum-transfer arthritis. To reveal whether
that reduction was due to a cell-autonomous migration defect, we
generated mixed bone marrow chimeras carrying CD45.1-
expressing wild type, along with CD45.2-expressing wild type or
Card9 / hematopoietic tissues (WT: WT and WT: Card9 /
chimeras, respectively). Those chimeras were subjected to
K/BN serum-transfer arthritis and the ability of myeloid cells
from the different genotypes to inﬁltrate the inﬂamed synovium
was tested by comparing the ratio of CD45.1-expressing and
CD45.2-expressing cells in the peripheral blood and synovial
inﬁltrate. As shown in Fig. 3c and Supplementary Fig. 3a, no
signiﬁcant difference between the percentage of CD45.2-positive
neutrophils in the blood and synovium was observed in any
of the mixed bone marrow chimeras irrespective of the genotype
(wild type or Card9 / ) of the CD45.2-positive population
(P¼ 0.80 for normalized data shown in Supplementary Fig. 3a;
Student’s t-test). Similarly, the percentage of CD45.2-positive
monocytes in the blood was always similar to that of CD45.2-
positive macrophages in the synovium, irrespective of the geno-
type of the CD45.2-positive cells (Fig. 3d and Supplementary
Fig. 3b; P¼ 0.56; Student’s t-test). Those results indicated that
Card9 / myeloid cells did not have an intrinsic migration
defect in vivo.
We also tested the intrinsic migratory capacity of neutrophils
in in vitro transwell assays. As shown in Fig. 3e, the Card9 /
mutation did not affect the migration of neutrophils towards
fMLP (P¼ 0.71; two-way ANOVA), MIP-2 (CXCL2; P¼ 0.53;
two-way ANOVA) or LTB4 (P¼ 0.92; two-way ANOVA) as
chemoattractants either.
Taken together, Card9 / myeloid cells show partially
reduced accumulation at the site of inﬂammation despite no
cell-autonomous migration defect.
Decreased chemokine and cytokine but not LTB4 levels in vivo.
To resolve the apparent contradiction between partially
reduced accumulation but normal intrinsic migratory capacity of
Card9 / myeloid cells, we hypothesized that CARD9 was
required for the generation of an appropriate inﬂammatory
(chemoattractant) tissue microenvironment. Therefore, we tested
the presence of various pro-inﬂammatory mediators in the syno-
vial inﬁltrate. As shown in Fig. 4a,b, the Card9 / mutation led
to a strong reduction of the levels of various chemokines acting
on myeloid cells, including KC (CXCL1; P¼ 0.011; two-way
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Figure 1 | CARD9 is important for the development of autoantibody-induced arthritis. Intact wild type (WT), Card9 / (a–d) or Card9 / (EUCOMM)
(e,f) mice were injected with BN (control) or K/BN (arthritic) serum i.p. on day 0. Arthritis development was followed by photographing on day 7
(a), clinical scoring of the hind limbs (b,e), ankle-thickness measurement (c,f) and an articular function test (hanging on a wire grid; (d)). Images are
representative of, and quantitative data show mean and s.e.m. from 8 to 9 control and 12 to 13 arthritic serum-treated individual mice per group from
four independent experiments (a–d) or 5 to 6 control and 8 to 9 arthritic serum-treated mice per group from three independent experiments (e,f).
(d) Results from functional test performed 12 times on each mouse between days 7–10. *Po0.05 (two-way ANOVA); see the text for actual P values.
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ANOVA), MIP-1a (CCL3; P¼ 0.0013; two-way ANOVA) and
MIP-2 (CXCL2; P¼ 0.027; two-way ANOVA), as well as the
IL-1b cytokine (P¼ 2.5 10–5; two-way ANOVA). Interestingly,
however, the Card9 / mutation did not affect the level of the
lipid chemoattractant LTB4 at the site of inﬂammation (Fig. 4c;
P¼ 0.77; two-way ANOVA). Those results likely explain
the substantially but not completely reduced accumulation of
myeloid cells in the inﬂamed synovium.
Neutrophil CARD9 is required for in vivo inﬂammation. The
importance of neutrophils in autoantibody-induced inﬂamma-
tion28,34 and the apparent role of CARD9 in a radiosensitive
hematopoietic compartment (Supplementary Fig. 2) raised the
possibility that CARD9 expressed in neutrophils was required for
the autoantibody-induced arthritis and dermatitis response. The
availability of the Card9tm1a(EUCOMM)Hmgu allele that allows
further manipulation towards lineage-speciﬁc deletion provided a
unique opportunity to test the functional relevance of CARD9
speciﬁcally within the neutrophil lineage.
Using FRT-mediated manipulation of the Card9tm1a(EU-
COMM)Hmgu knockout-ﬁrst allele (Supplementary Fig. 4), we
have generated mice carrying the Card9tm1c(EUCOMM)Hmgu
(referred to as Card9ﬂox) ﬂoxed allele and bred those mice to
MRP8-Cre35 transgene-expressing mice to generate MRP8-
CreþCard9ﬂox/ﬂox (referred to as Card9DPMN) mice with
lineage-speciﬁc deletion of CARD9 speciﬁcally in the neutrophil
compartment (Supplementary Fig. 4). As shown in Fig. 5a, FACS-
sorted Card9 / neutrophils had no detectable CARD9
expression, whereas the level of CARD9 was strongly reduced
(though not completely absent) in similarly sorted Card9DPMN
neutrophils. However, in agreement with prior studies showing
high selectivity of the MRP8-Cre transgene35,36, the Card9DPMN
mutation did not affect CARD9 expression in bone marrow-
derived macrophages (Fig. 5b). Those results conﬁrmed the
effective and speciﬁc deletion of CARD9 from Card9DPMN
neutrophils.
We next tested the effect of the Card9DPMN mutation on
K/BN serum-transfer arthritis. As shown in Fig. 5c, both the
Card9 / (P¼ 1.4 10–6; two-way ANOVA) and the
Card9DPMN (P¼ 4 10–4; two-way ANOVA) mutations caused
a substantial but incomplete reduction of the clinical arthritis score.
Similarly, the ankle-thickening response (Fig. 5d) was reduced in
both Card9 / (P¼ 4.3 10–4; two-way ANOVA) and
Card9DPMN (P¼ 0.0069; two-way ANOVA) mutants. Importantly,
there was practically no difference between the effect of neutrophil-
speciﬁc and complete CARD9 deﬁciency in either assay readouts
tested (P values between 0.47 and 0.56; two-way ANOVA).
We have also subjected the same mutants to the autoantibody-
induced skin blistering disease model. As shown in Fig. 5e, both
the Card9 / (P¼ 4.6 10–6; two-way ANOVA) and the
Card9DPMN (P¼ 1.7 10–5; two-way ANOVA) mutants were
signiﬁcantly but not completely protected from disease develop-
ment deﬁned as the body area affected. Similarly, the clinical
score (Fig. 5f) was reduced in both Card9 / (P¼ 1.6 10–4;
two-way ANOVA) and Card9DPMN (P¼ 7.5 10–5; two-way
ANOVA) mutants. Again, the two mutant strains showed
practically identical phenotypes in both assay readouts tested
(P values between 0.17 and 0.69; two-way ANOVA).
Taken together, the defective arthritis and dermatitis develop-
ment in Card9 / mice is mostly due to the role of CARD9
within the neutrophil compartment.
Reduced neutrophil chemokine/cytokine but not LTB4 release.
Given the in vivo role of CARD9 within neutrophils, we next
tested various in vitro functions of Card9 / neutrophils. Those
experiments focused on immune complex-induced activation as
an in vitro model of autoantibody-induced in vivo activation.
Although Card9 / neutrophils lacked the CARD9 protein
(Supplementary Fig. 5a), they expressed normal levels of the
neutrophil maturation marker Ly6G (Supplementary Fig. 5b),
and showed normal expression of cell surface FcgRII/III and
FcgRIV (Supplementary Fig. 5c).
CARD9 deﬁciency did not affect immune complex-induced
short-term functional responses of neutrophils such as superoxide
Control
Control
Anti-CVII
Anti-CVII
WT
Card9–/–
Card9–/– control
Card9–/–
Card9–/–
Card9–/– anti-CVII
WT anti-CVII
WT control
Card9–/– control
Card9–/– anti-CVII
WT anti-CVII
WT control
WT
WT
* Card9–/–
WT
*
30
20
10
0
0 2 4 6 8 10 12 14
Time (days)
0 2 4 6 8 10 12 14
Time (days)
Bo
dy
 s
ur
fa
ce
 a
ffe
ct
ed
 (%
)
Cl
in
ica
l s
co
re
6
4
2
0
NS
0.8
0.6
0.4
0.2
0
Se
ru
m
 a
nt
i-C
VI
I (O
D)
a
b c
d
Figure 2 | CARD9 in autoantibody-induced skin blistering disease.
Blistering skin disease was triggered in wild type (WT) and Card9 /
intact mice or bone marrow chimeras by systemic injection of collagen VII-
speciﬁc (anti-CVII) antibodies. Skin disease was followed by photographing
on day 14 (a) and clinical assessment of the total body surface affected
(b) and the overall disease severity (c). The serum titre of anti-CVII
antibodies was tested on day 6 by ELISA (d). Representative images (a) or
mean and s.e.m. (b–c) from 7 to 9 control (2 intact and 5–7 bone marrow
chimeric) and 13–14 anti-CVII-treated (2 intact and 11–12 bone marrow
chimeric) mice per genotype from four independent experiments are
shown. No difference between intact and chimeric mice of the same
hematopoietic genotype was observed (not shown). (d) Mean and s.e.m.
from 4 control and 12–13 anti-CVII-treated mice from ﬁve independent
experiments are shown. *Po0.05; NS, statistically not signiﬁcant (two-way
ANOVA); see the text for actual P values.
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release (Fig. 6a; P¼ 0.79; two-way ANOVA) or the exocytosis of
gelatinase-containing granules (Fig. 6b). However, CARD9
deﬁciency markedly reduced the immune complex-induced
release of MIP-1a (P¼ 0.0079; two-way ANOVA) and MIP-2
(P¼ 1.2 10–7; two-way ANOVA) chemokines from neutrophils
(Fig. 6c). As shown in Fig. 6d, Card9 / neutrophils also showed
strong reduction of the immune complex-induced expression of
the genes encoding for IL-1b (P¼ 0.018; two-way ANOVA), KC
(P¼ 6.0 10–16; two-way ANOVA), MIP-1a (P¼ 9.6 10–7; two-
way ANOVA) and MIP-2 (P¼ 6.2 10–8; two-way ANOVA).
We have also performed complementary DNA (cDNA) micro-
array analysis to test whether the reduced upregulation of
chemokine and cytokine genes reﬂected a generalized defect of
immune complex-induced gene expression (Fig. 6e,f; Supplementary
Table 1). As shown in the heat map of the 50 most highly
upregulated genes (Fig. 6e), CARD9 deﬁciency led to an overall
decrease of immune complex-induced upregulation of neutrophil
gene expression, including expression of various genes expressing
pro-inﬂammatory mediators. The average changes of the expression
of the genes shown in Fig. 6e has also been summarized in Fig. 6f,
which indicated a 78% reduction of immune complex-induced gene
expression in Card9 / cells (Po10-17; two-way ANOVA).
In contrast to the various chemokines and cytokines, the
immune complex-induced release of LTB4 from neutrophils was
not affected by the Card9 / mutation (Fig. 6g; P¼ 0.39; two-
way ANOVA). In addition, the expression of Alox5 that encodes
for 5-lipoxigenase, the rate-limiting enzyme of LTB4 synthesis, is
not triggered by immune complex stimulation in wild-type
neutrophils (P¼ 0.56; one-way ANOVA) and it is not affected by
the Card9 / mutation either (Fig. 6h). The expression of
Alox5ap and Lta4h, the other two components of LTB4 synthesis,
was also not altered by immune complex stimulation (P¼ 0.49
and 0.64, respectively; one-way ANOVA) or CARD9 deﬁciency
(Fig. 6i).
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Figure 3 | CARD9 plays no direct role in myeloid cell migration to the site of inﬂammation. Wild type (WT) and Card9 / mice were subjected to
K/BN serum-transfer arthritis (a–d), the ankle area or the front paw was ﬂushed on day 4 and the number of neutrophils (a) or monocytes/
macrophages (b) was determined by ﬂow cytometry. Mixed bone marrow chimeras with CD45.1-expressing wild type (WT) and CD45.2-expressing WTor
Card9 / hematopoietic cells were subjected to K/BN serum-transfer arthritis and in vivo accumulation of neutrophils (c) and monocytes/
macrophages (d) was determined by ﬂushing the synovial area on day 4, followed by ﬂow cytometric analysis of the ratio of CD45.1 and CD45.2-
expressing cells in peripheral blood and the synovial inﬁltrate. In (c,d), each dot represents an individual mouse. (e) In vitro migration of WTand Card9 /
bone marrow neutrophils towards the indicated chemoattractants in a ﬁbrinogen-coated Transwell system. Graphs represent mean and s.e.m. from 5–14
(a) or 6–16 (b) mice per group from ﬁve independent experiments. (e) Data represent mean and s.e.m. of three to ﬁve independent experiments. *Po0.05;
NS, statistically not signiﬁcant (Student’s t-test (a,b), two-way ANOVA (e)); see the text for actual P values.
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Taken together, CARD9 is required for immune complex-
induced gene expression changes and release of various
chemokines and cytokines but not LTB4 from neutrophils.
Together with the defective inﬂammatory response in neutro-
phil-speciﬁc CARD9 deletion mutants (Fig. 5), these results also
provide strong evidence for the in vivo role of gene expression
changes within the neutrophil compartment.
Upstream and downstream signalling components. Having
established a critical role for CARD9-mediated neutrophil gene
expression changes and chemokine/cytokine release, we ﬁnally
aimed to characterize the signalling components upstream and
downstream of CARD9 in neutrophils. We and others have pre-
viously shown that myeloid Src-family kinases (Hck, Fgr and Lyn)32,
Syk31,37 and PLCg2 (refs 29,30) are required for immune complex-
induced neutrophil functions and the K/BN serum-transfer
arthritis, supposedly by forming a receptor-proximal signalling
cluster. We therefore compared immune complex-induced
functional responses of neutrophils lacking those molecules with
responses of Card9 / cells. As shown in Fig. 7a, Hck /
Fgr /Lyn / (3 SFK KO), Syk / and Plcg2 /
neutrophils showed complete defect in immune complex-induced
superoxide production (P values between 7.9 10–5 and 1.6 10–4;
two-way ANOVA), whereas Card9 / cell showed a normal
response (P¼ 0.73; two-way ANOVA). Similarly, as shown in
Fig. 7b,c, while Hck /Fgr /Lyn / , Syk / and Plcg2 /
neutrophils showed complete defect in immune complex-induced
MIP-2 and LTB4 release (P values between 2.9 10–4 and
9.4 10–3; two-way ANOVA), Card9 / neutrophils displayed a
strong but incomplete reduction of MIP-2 release (P¼ 0.027; two-
way ANOVA) and no signiﬁcant reduction of LTB4 release
(P¼ 0.38; two-way ANOVA). The Card9 / neutrophil
phenotype was not due to defective receptor-proximal signalling
since Card9 / neutrophils showed normal Syk phosphorylation
on activation by immobilized immune complexes (Fig. 7d). Those
results suggest that CARD9 functions downstream of the receptor-
proximal Src-family/Syk/PLCg2 complex during immune complex-
induced neutrophil activation.
During fungal infection, CARD9 coordinates anti-fungal host
defence in cooperation with the downstream adapter Bcl10
(ref. 7). Therefore, we tested neutrophil functions and arthritis
development in the absence of Bcl10. Bcl10 / neutrophils
lacked the Bcl10 protein (Supplementary Fig. 6a) but expressed
normal levels of Ly6G (Supplementary Fig. 6b) and Fcg-receptors
(Supplementary Fig. 6c). On immune complex challenge,
Bcl10 / neutrophils showed normal superoxide release
(Fig. 7e; P¼ 0.76; two-way ANOVA) but defective release of
the MIP-2 chemokine (Fig. 7f; P¼ 0.0057; two-way ANOVA). As
shown in Supplementary Fig. 7, the Bcl10 / mutation also
caused partial protection from the clinical signs (P¼ 0.065; two-
way ANOVA) and ankle-thickening response (P¼ 0.015; two-
way ANOVA) during K/BN serum-transfer arthritis. The
CARD9-Bcl10 complex is thought to signal through the Malt1
paracaspase during antifungal immunity7. As shown in Fig. 7g,h,
Malt1 / neutrophils produced normal levels of superoxide on
immune complex activation (P¼ 0.87; two-way ANOVA) but
their MIP-2 release was substantially reduced under identical
conditions (P¼ 0.0092; two-way ANOVA). The similarity
between the Card9 / , Bcl10 / and Malt1 / phenotypes
suggests that Bcl10 and Malt1 participates in signalling
downstream of CARD9 during immune complex-induced
neutrophil activation.
We have also explored how CARD9 is coupled to upregulation
of pro-inﬂammatory gene expression. CARD9 deﬁciency strongly
reduced immune complex-induced phosphorylation and
degradation of IkBa (Fig. 7i) and the translocation of NFkB
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p65 to the nucleus (Fig. 7j), indicating that CARD9 triggers
upregulation of inﬂammatory gene expression through activation
of the canonical NFkB pathway.
Taken together, the CARD9 signalling pathway respon-
sible for chemokine/cytokine production by neutrophils
during inﬂammation in vivo is reminiscent of the signa-
lling pathway utilized by C-type lectin receptors and
consists of a receptor-proximal Src-family/Syk/PLCg2 module
triggering NFkB activation through the CARD9/Bcl10/Malt1
complex.
Discussion
Our results indicate that the CARD9 protein expressed within the
neutrophil compartment plays an important role in chemokine
and cytokine but not LTB4 release during autoantibody-induced
sterile inﬂammation. To our knowledge, these are the ﬁrst
experiments showing that neutrophil-speciﬁc abrogation of
agonist-induced gene expression changes (without affecting other
neutrophil functions) inhibits in vivo inﬂammatory reactions and
therefore provide the most direct evidence so far for an important
in vivo role of inﬂammation-induced gene expression changes
within the neutrophil lineage.
Although neutrophils have long been known to be critical
effector cells of antimicrobial host defence, more recent studies
indicated that they are also capable of releasing pro-inﬂammatory
mediators5,6. Unfortunately, direct evidence for the role of
neutrophil gene expression or neutrophil-derived chemokines/
cytokines has been missing. A number of prior studies reported a
critical role for neutrophils in in vivo inﬂammatory reactions2,28
and a recent study has shown that neutrophil-speciﬁc deletion of
Syk blocked arthritis development in the K/BN serum-transfer
model37. Unfortunately, since those approaches not only
blocked neutrophil-derived gene expression but also other
functional responses of those cells, the speciﬁc effect of gene
expression changes could not be assessed. Other attempts
utilized complementation approaches using mixed bone
marrow chimeras or isolated bone marrow neutrophils27,38,39.
Unfortunately, all those approaches had major limitations related
to the limited speciﬁcity of the Gﬁ1 / strain used or the limited
purity and altered activation status of ex vivo isolated bone
marrow-derived neutrophils. Our results with the Card9DPMN
mutants (Fig. 5) provide the ﬁrst direct evidence using
lineage-speciﬁc deletion that the products of neutrophil gene
expression coordinate the in vivo inﬂammatory response without
affecting conventional neutrophil functions such as reactive
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oxygen species (ROS) release. Our overall study also suggests that
neutrophil-derived LTB4 is capable of driving a clinically evident,
though substantially reduced level of neutrophil-mediated
inﬂammation even in the absence of neutrophil-derived
chemokines and cytokines. Those results together provide
substantial novel insight into the in vivo role of neutrophil gene
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expression and neutrophil-derived mediators during the
inﬂammatory response.
The role of CARD9 has so far mainly been tested in functional
responses of dendritic cells and macrophages, myeloid cell types
primarily implicated in the organization of an adaptive immune
response. Though we have observed that Card9 / macro-
phages also show defective chemokine but not ROS release
(Supplementary Fig. 8), our lineage-speciﬁc studies indicate that,
at least in our experimental system, the effect of CARD9
deﬁciency is primarily due to the CARD9 expression in
neutrophils. This is further supported by the presence of normal
levels of CARD9 in Card9DPMN macrophages.
A crucial question related to the interpretation of our lineage-
speciﬁc deletion studies is the speciﬁcity of the MRP8-Cre
transgene. The MRP8 (S100A8) protein is also expressed in other
myeloid cells such as macrophages, and therefore Cre-mediated
deletion of target genes could have been predicted also in
macrophages. However, the fact that CARD9 is expressed
normally in Card9DPMN bone marrow-derived (Fig. 5b) macro-
phages indicates that this is not the case. Indeed, the original
description of the MRP8-Cre transgene35 indicated high
speciﬁcity towards neutrophils and detailed recent studies have
also shown negligible deletion of ﬂoxed genomic sequences in
MRP8-Cre transgene-positive macrophages or dendritic cells36,37.
This high speciﬁcity may be due to the fact that MRP8 is likely
the most abundant cytoplasmic protein in neutrophils and the
ImmGen database23 indicates that it is expressed at 20–100-fold
higher levels in neutrophils than in any other myeloid lineage cell
types. Those results together provide convincing evidence that the
in vivo phenotypes of the Card9DPMN mutants are due to speciﬁc
deletion of CARD9 from the neutrophil lineage.
Although the role of CARD9 in antifungal and other
antimicrobial immunity is well established7, its role in non-
infectious inﬂammation is poorly understood. The protection
of Card9 / mice from autoantibody-induced inﬂammatory
reactions and the defective responses of Card9 / cells to
immune complex stimulation indicate a critical role for CARD9
also in non-infectious inﬂammatory processes. This issue is
particularly important given the association of CARD9
polymorphisms with rheumatoid arthritis, inﬂammatory bowel
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disease, ankylosing spondylitis or IgA nephropathy14–21, major
human inﬂammatory diseases of non-infectious origin.
IgA nephropathy, the most frequent form of primary glomerulo-
nephritis in humans, is particularly interesting since it is caused by
immune complex deposition at the glomerular basement
membrane40. As neutrophils are the primary cell types
responding to systemic IgA through the human-speciﬁc FcaRI
(CD89) molecule41, it is tempting to speculate that, similar to our
studies in mice, the potential role of CARD9 in IgA nephropathy is
due to its role in immune complex-induced neutrophil activation.
Autoantibody-induced inﬂammation has been shown to be
mediated by a lipid-cytokine-chemokine cascade27, which also
triggers autoampliﬁcation of leucocyte recruitment42. We and
others have previously shown that a receptor-proximal
Src-family/Syk/PLCg2 signalling module is critical for
autoantibody-induced arthritis and dermatitis29–32,37,43.
However, it has been unclear how that signalling module is
coupled to chemokine, cytokine and lipid mediator release. Our
results indicate that CARD9 acts as a divergence point
downstream of the receptor-proximal Src-family/Syk/PLCg2
module in neutrophils and leads to Bcl10/Malt1- and
NFkB-dependent chemokine and cytokine release without
playing a role in lipid mediator (LTB4) production
(Supplementary Fig. 9). Those results reveal intricate details of
myeloid cell signalling during autoantibody-induced
inﬂammation. The normal LTB4 release also likely explains why
Card9 / animals are only partially protected from arthritis and
dermatitis development.
Though it is not entirely clear how the CARD9–Bcl10–Malt1
complex activates the NFkB pathway, the mechanism of
activation and nuclear translocation of NFkB by the CARD9-
related CARMA-like proteins has been investigated in other
immune cells. Assembly of CARMA proteins with Bcl10 and
Malt1 leads to the ubiquitination of the regulatory IkBa kinase
subunit NEMO and the phosphorylation and degradation of
IkBa(ref 44). CARMA-like proteins supposedly exert their effect
through binding to TRAF6 and recruiting TAK1 to the CARMA-
Bcl10-Malt1 complex, where TAK1 activates IKK leading to the
above-mentioned IkBa phosphorylation45. Furthermore,
activated Malt1 inactivates the negative regulator of NFkB
signalling7.
Taken together, our experiments reported here provide
substantial novel insight and mechanistic detail about various
aspects of the inﬂammatory reaction, including (1) the in vivo
role of neutrophil gene expression and chemokine/cytokine
release; (2) the contribution of CARD9 to non-infectious
inﬂammation and (3) the pathways coupling immunoreceptors
to cellular effector functions (Supplementary Fig. 9). Those results
will improve our understanding of the pathomechanism of
autoimmune and inﬂammatory diseases and may contribute to
the development of novel diagnostic and therapeutic strategies in
the future.
Methods
Animals. Mice homozygous for the Card9tm1Jrld, Bcl10tm1Mak, Malt1tm1Jrld or
Plcg2tm1JnI mutations (referred to as Card9 / , Bcl10 / , Malt1 / and
Plcg2 / mutants, respectively) or triple homozygous for the Hcktm1Hev,
Fgrtm1Hev and Lyntm1Sor mutations (referred to as Hck /Fgr /Lyn / or
3 SFK KO mice) were described previously8,46–49. Heterozygous mice carrying
a deleted Syk allele (Syktm1Tyb, referred to as Syk–) were time-mated and
their embryos were used to generate bone marrow chimeras with a Syk /
hematopoietic system as described31. Mice homozygous for the
Card9tm1a(EUCOMM)Hmgu knockout-ﬁrst mutation33 (referred to as Card9 /
(EUCOMM) mice) were obtained from the Wellcome Trust Sanger Institute
(EUCOMM Project No. 44813). Mice carrying the Card9tm1a(EUCOMM)Hmgu
knockout-ﬁrst mutation were also bred to the FLPeR deleter strain50 to remove the
FRT-ﬂanked knockout-ﬁrst cassette generating the Card9tm1c(EUCOMM)Hmgu
ﬂoxed allele (referred to as Card9ﬂox), followed by breeding to the MRP8-Cre
transgenic mice35 to generate MRP8-CreþCard9ﬂox/ﬂox (referred to as
Card9DPMN) mice with a neutrophil-speciﬁc CARD9 deletion. Mice carrying the
KRN T-cell-receptor transgene51 were obtained from Diane Mathis and Christophe
Benoist (Harvard Medical School) and maintained in heterozygous form by mating
with C57BL/6 mice.
All transgenic mice were backcrossed to the C57BL/6 genetic background for at
least six generations. Genotyping was performed by allele-speciﬁc PCR.
Wild-type control C57BL/6 mice were purchased from Charles River or the
Hungarian National Institute of Oncology (Budapest, Hungary). NOD mice, as
well as a congenic strain carrying the CD45.1 allele on the C57BL/6 genetic
background (B6.SJL-Ptprca) were purchased from the Jackson Laboratory.
Mice were kept in individually sterile ventilated cages (Tecniplast) in a
conventional facility. All animal experiments were approved by the Animal
Experimentation Review Board of the Semmelweis University.
Bone marrow chimeras were generated by intravenous injection of bone
marrow cells into recipients carrying the CD45.1 allele on the C57BL/6 genetic
background, which were lethally irradiated before by 11 Gy from a 137Cs source
using a Gamma-Service Medical (Leipzig, Germany) D1 irradiator. Four weeks
after transplantation, peripheral blood samples were stained for Ly6G and CD45.2
(at a ﬁnal concentration of 2 mgml 1) and analysed by ﬂow cytometry as
previously described32.
Mice of both genders at 2–6 months of age were used for the experiments.
K/BN serum-transfer arthritis. Mice carrying the KRN T-cell receptor
transgene on the C57BL/6 genetic background were mated with NOD mice
to obtain transgene-positive (arthritic) K/BN and transgene-negative
(non-arthritic) BN mice30,51. The presence of the transgene was determined by
allele-speciﬁc PCR and conﬁrmed by phenotypic assessment. Blood was taken by
retroorbital bleeding and sera from arthritic and control mice were pooled
separately.
Arthritis was induced by a single intraperitoneal injection of 300 ml K/BN
(arthritic) or BN (control) serum into intact mice or bone marrow chimeras,
followed by daily assessment of arthritis severity for 2 weeks as described30. Visible
clinical signs were scored on a 0–10 scale by two investigators blinded for the origin
and treatment of the mice. Ankle thickness was measured by a spring-loaded
caliper (Kroeplin).
To investigate serum-induced articular dysfunction, mice were placed on a
custom-made (Charles River Hungary, Isaszeg, Hungary) wire grid, slowly ﬂipped
and the length of time the mice held on to the grid was recorded as described30.
The obtained data were combined into ‘holding-on curves’ for each mouse.
Autoantibody-induced skin blistering model. The murine model of the human
blistering skin disease epidermolysis bullosa acquisita was triggered by systemic
administration of antibodies against collagen type VII(ref 25). The bacterial
expression of GST fusion proteins containing the mCVIICr fragment of mouse
collagen VII, its puriﬁcation, the generation of polyclonal antiserum in rabbits and
IgG fraction separation were carried out as previously described25,52. The reactivity
of the antibody preparation was tested with His-tagged mCVIICr fragment of
murine collagen VII using an enzyme-linked immunosorbent assay (ELISA) as
described52. Normal rabbit IgG (Sigma) or PBS was used as control.
Twelve milligrams of pathogenic or control IgG per mouse was injected
subcutaneously under isoﬂurane anaesthesia on days 0, 2, 4, 6 and 8 (60 mg total
IgG/mouse). The disease onset and progression was followed by clinical assessment
every second day. Scoring was based on the speciﬁc dermatological abnormalities
(for example, erythema, blister, crust) and the size of the affected skin area, the
latter one determined by using predeﬁned percentages of the various areas of the
skin of mice (for example, one ear: 2.5%; snout: 5% and so on). Antibody levels
against collagen VII in blood samples at day 6 were determined by ELISA.
In vivo analysis of myeloid cell migration. In case of the K/BN serum-transfer
model, the ankle or front paw area was ﬂushed with 1ml PBS supplemented with
10mM EDTA (pH 7.5) and 20mM HEPES (pH 7.4; Sigma) on day 4 to obtain a
sample of synovial inﬁltrate. The number and distribution of the myeloid cells in
the resulting suspension was then determined by ﬂow cytometry. Cells were
identiﬁed based on their forward- and side-scatter characteristics, as well as by
positive staining of neutrophils for Ly6G (clone 1A8 from BD Biosciences; ﬁnal
concentration: 2 mgml 1), or positive staining of monocytes/macrophages for
F4/80 (Clone: A3-1, AbD Serotec; ﬁnal concentration: 10 mgml 1) or CD11b
(Clone: M1/70, BD Biosciences; ﬁnal concentration: 2 mgml 1) within the
Ly6G-negative gate.
A competitive migration assay in mixed bone marrow chimeras30 was also used
to assess in vivo migration of myeloid cells. To this end, wild type (C57BL/6) or
Card9 / bone marrow cells (all carrying the CD45.2 allele) were mixed at
varying ratios with bone marrow cells from congenic mice expressing CD45.1 on
the C57BL/6 genetic background. This mixed cell suspension was injected
intravenously into lethally irradiated CD45.1-expressing recipient mice, giving
rise to mixed bone marrow chimeras carrying CD45.2-expressing wild type or
Card9 / along with CD45.1-expressing wild type hematopoietic cells within the
same animals. After the repopulation of the bone marrow, the chimeras were
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subjected to K/BN serum-transfer arthritis and their synovial inﬁltrates were
prepared as described above. The percentage of CD45.2-expressing cells were
analysed by ﬂow cytometry as described above, with an additional staining for
CD45.2 (Clone: 104, BD Biosciences; ﬁnal concentration: 2 mgml 1).
Relative migration (accumulation) of the CD45.2-positive neutrophils or
monocytes/macrophages (relative to the CD45.1-expressing wild-type cells) was
calculated as described32.
Isolation and activation of neutrophils and macrophages. Mouse neutrophils
were isolated from the bone marrow of the femurs and tibias of intact mice or
chimeras by hypotonic lysis followed by Percoll (GE Healthcare) gradient cen-
trifugation using sterile and endotoxin-free reagents as described53. Cells were kept
at room temperature in Ca2þ - and Mg2þ -free medium until use and prewarmed
to 37 C prior to activation. Neutrophil assays were performed at 37 C in Hanks’
Balanced Salt Solution (HBSS) supplemented with 20mM HEPES, pH 7.4.
Neutrophil cell surface Fcg receptor expression was detected by anti-FcgRII/III
(Clone: 2.4G2, BD Biosciences; ﬁnal concentration: 2 mgml 1) and anti-FcgRIV
antibodies (ﬁnal concentration: 10.2 mgml 1), followed by a secondary staining
with ﬂuorochrome-conjugated Mouse anti-rat and Mouse anti-hamster antibodies
(Clones: MRK-1 and G70-204/G94-56, respectively, both from BD Biosciences;
ﬁnal concentration: 1 mgml 1).
Mouse bone marrow-derived macrophages were obtained by culturing bone
marrow cells from intact mice in a-MEM (Sigma) complemented with 10% FCS
(Invitrogen), 2mM L-glutamine, antibiotics, 10mM HEPES (all from Sigma) and
10% conditioned medium from CMG 14-12 cells as a source of recombinant
murine M-CSF54 for 8 days on bacterial Petri dishes with media changes every 2–3
days. Cells were suspended by 5mM EDTA, washed and serum-starved for 2 h
before the experiments.
To obtain immobilized immune complex-coated surfaces, human serum
albumin (Sigma) or lactoferrin (Sigma) was either bound directly to regular or
luminometric Nunc MaxiSorp F96 (Thermo Fisher) plates or covalently linked to
poly-L-lysine-coated 24-well tissue culture plates or 6-cm tissue culture dishes and
then treated with anti-human serum albumin or anti-lactoferrin IgG (Sigma) as
described55.
For the analysis of cytokine release, 100 or 500 ml aliquots of 4 106 per ml
neutrophils or 500ml aliquots of 3 106 per ml macrophages suspended in HBSS
supplemented with 20mM HEPES, pH 7.4 were plated on immobilized immune
complex surfaces in 96-well ELISA plates or 24-well tissue culture plates,
stimulated for 6 h (neutrophils) or 24 h (macrophages) and the inﬂammatory
mediator concentration of the supernatant was determined. For the analysis of
LTB4 production, 100ml aliquots of 4 106 per ml neutrophils suspended in
DMEM (Sigma) were plated on immobilized immune complex surfaces in 96-well
ELISA plates for 1 h and the LTB4 concentration of the cell-free supernatant was
measured. Superoxide release by neutrophils was followed by a cytochrome c
reduction test from 100 ml aliquots of 4 106 per ml cells plated on immune
complex-coated surfaces in 96-well ELISA plates as described56. To test ROS
production by macrophages, 100 ml aliquots of 3 106 per ml cells were plated on
immune complex-coated surfaces in 96-well luminometric ELISA plates in the
presence of 50 mgml 1 lucigenin (Sigma) and the chemiluminescence of the
samples was followed by a Berthold (Bad Wildbad, Germany) Mithras LB 940
luminometer. The release of gelatinase was determined by gelatinase zymography
as previously described56.
In vitro migration of neutrophils was tested by using a Transwell (Corning)
assay with inserts of 3 mm pore size coated with human ﬁbrinogen as described30.
Three microlitres of fMLP (Sigma), 100 ngml 1 MIP-2 (Peprotech) or 50 ngml 1
LTB4 (Santa Cruz Biotechnology) was used as chemoattractants. Transmigrated
cells were measured by an acid phosphatase assay30.
Analysis of inﬂammatory mediators. The release of inﬂammatory mediators was
tested from the cell-free supernatants of synovial inﬁltrates gathered on day 4 or of
in vitro stimulated neutrophils or macrophages. The levels of IL-1b, KC, MIP-1a
and MIP-2, as well as of the lipid mediator LTB4, were tested by commercial ELISA
kits (R&D Systems) according to the manufacturer’s instructions.
Gene expression measurements. For in vitro gene expression studies, 500 ml
aliquots of 4 106 per ml neutrophils suspended in HBSS supplemented with
20mM HEPES, pH 7.4 were plated on immobilized immune complex surfaces in
24-well tissue culture plates and stimulated for 4 h. The reaction was stopped on
ice and the cells (adherent and nonadherent combined) were lysed and total
RNA were prepared by the RNeasy Micro Kit (Qiagen). RNA samples were
reverse transcripted to cDNA by the cDNA Synthesis Kit (Thermo Scientiﬁc)
and were kept at  70 C until use. The expression of unique genes was analysed
using the TaqMan probes Mm01336189_m1 (Il1b), Mm00433859_m1 (Cxcl1),
Mm00436450_m1 (Cxcl2), Mm00441258_m1 (Ccl3), Mm01182747 (Alox5),
Mm00802100_m1 (Alox5ap), Mm00521826_m1 (Lta4h) and 4352932E (Gapdh)
(all from Applied Biosystems) on a Roche LightCycler 480 device in a
white 96-well plate. Global gene expression was measured by Affymetrix
Microarrays at the UD GenoMed (Debrecen, Hungary) according to the
manufacturer s instructions. More information and the raw data ﬁles are
available in the Gene Expression Omnibus database under the accession number
GSE78066.
Biochemical studies. For analysis of Syk phosphorylation, 6 106 neutrophils in
1.2ml assay buffer were plated on immune complex-covered 6-cm tissue culture
dishes and incubated for 10min at 37 C. The reaction was stopped on ice and the
cells (adherent and nonadherent combined) were lysed in 100mM NaCl, 30mM
Na-HEPES (pH 7.4), 20mM NaF, 1mM Na-EGTA, 1% Triton X-100, 1mM
benzamidine, freshly supplemented with 0.1Uml 1 Aprotinin, 1:100 Mammalian
Protease Inhibitor Cocktail, 1:100 Phosphatase Inhibitor Cocktail 2, 1mM
phenylmethylsulphonyl ﬂuoride and 1mM Na3VO4 (all from Sigma). After
removal of insoluble material, lysates were either boiled in sample buffer or
processed for immunoprecipitation. Immunoprecipitation of Syk was performed
by an anti-Syk antibody (Clone: 5F5; BioLegend; ﬁnal concentration: 4.4 mgml 1)
followed by a capturing step with Protein G-Agarose (Invitrogen) as
described57–59.
For analysis of IkBa phosphorylation and degradation, 2 106 neutrophils in
0.5ml assay buffer were plated on immune complex-covered 24-well tissue culture
plates and incubated for 20min at 37 C. The reaction was stopped on ice and the
cells were lysed as described above. During the electrophoretic mobility shift assay,
NFkB activation and nuclear translocation was followed using the same setup, but
the cells were lysed with NP40 in the presence of dithiothreitol and
phenylmethylsulphonyl ﬂuoride. Nuclear extracts were prepared and were run on
an acrylamide gel in the presence of infrared dye-labelled NFkB-binding-site-
containing oligonucleotides (Licor) as described before8.
To test the efﬁcacy of neutrophil-speciﬁc CARD9 deletion, neutrophils from
mice of different genotypes were sorted on the basis of their Ly6G-staining on a
FACSAria ﬂow cytometer (BD Biosciences) from red blood cell-lysed bone marrow
cell suspensions.
Whole cell lysates and immunoprecipitates were run on SDS–polyacrylamide
gel electrophoresis and immunoblotted using antibodies against phospho-
tyrosine (Clone: 4G10, Merck Millipore; ﬁnal concentration: 1 mgml 1), Syk
(Clone: N19, Santa Cruz Biotechnology; ﬁnal concentration: 0.2 mgml 1),
IkBa (Cell Signaling; dilution: 1:1,000), phospho- IkBa (Cell Signaling,
dilution: 1:1,000), CARD9 (Clone: H-90, Santa Cruz Biotechnology; ﬁnal
concentration: 0.2 mgml 1), Bcl10 (Clone: H-197, Santa Cruz Biotechnology;
ﬁnal concentration: 0.2 mgml 1) or b-actin (Clone: AC-74, Sigma;
dilution: 1:5,000) followed by peroxidase-labelled secondary antibodies
(GE Healthcare; dilution: 1:5,000). The signal was developed using the ECL
system (GE Healthcare) and exposed to X-ray ﬁlm. Western blots with more
details are available in Supplementary Fig. 10.
Presentation of the data and statistical analysis. Experiments were performed
the indicated number of times. Quantitative graphs and kinetic curves show mean
and s.e.m. from all independent in vitro experiments or from all individual mice
from the indicated number of experiments. Unless otherwise stated, statistical
analyses were carried out using two-way (factorial) ANOVA, with treatment and
genotype being the two independent variables. In case of kinetic assays, area under
the curve was used for statistical analysis. P values below 0.05 were considered
statistically signiﬁcant.
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